Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05603910
Title	Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
Recruitment	Recruiting
Gender	female
Phase	Phase I
Variant Requirements	Yes
Sponsors	Aaron Wolfson
Indications	endometrial adenocarcinoma endometrial serous adenocarcinoma endometrial carcinoma endometrial mixed adenocarcinoma endometrial clear cell adenocarcinoma endometrial adenosquamous carcinoma endometrial mucinous adenocarcinoma
Therapies	Lenvatinib + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA